SRx Health Solutions Inc.
SRx Health Solutions Inc. (SRXH) Stock Competitors & Peer Comparison
See (SRXH) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SRXH | $0.13 | -9.42% | 4.3M | -0.74 | -$0.17 | N/A |
| LLY | $1,004.92 | -0.18% | 946.1B | 35.70 | $28.14 | +0.65% |
| JNJ | $226.71 | -1.77% | 545.8B | 26.27 | $8.63 | +2.28% |
| ABBV | $210.39 | -0.18% | 371.8B | 103.15 | $2.04 | +3.20% |
| NVS | $148.08 | -1.13% | 282.5B | 21.21 | $6.98 | +3.20% |
| AZN | $181.58 | -1.83% | 281.8B | 27.32 | $6.65 | +1.76% |
| MRK | $111.38 | -1.79% | 275.1B | 31.38 | $3.55 | +2.98% |
| AMGN | $326.31 | -2.95% | 176.1B | 22.71 | $14.37 | +3.00% |
| GILD | $129.58 | -1.88% | 160.9B | 15.48 | $8.37 | +2.46% |
| PFE | $25.33 | -1.63% | 144.4B | 19.34 | $1.31 | +6.80% |
Stock Comparison
SRXH vs LLY Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, LLY has a market cap of 946.1B. Regarding current trading prices, SRXH is priced at $0.13, while LLY trades at $1,004.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas LLY's P/E ratio is 35.70. In terms of profitability, SRXH's ROE is +4.36%, compared to LLY's ROE of +1.01%. Regarding short-term risk, SRXH is more volatile compared to LLY. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check LLY's competition here
SRXH vs JNJ Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, JNJ has a market cap of 545.8B. Regarding current trading prices, SRXH is priced at $0.13, while JNJ trades at $226.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas JNJ's P/E ratio is 26.27. In terms of profitability, SRXH's ROE is +4.36%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, SRXH is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check JNJ's competition here
SRXH vs ABBV Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, ABBV has a market cap of 371.8B. Regarding current trading prices, SRXH is priced at $0.13, while ABBV trades at $210.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas ABBV's P/E ratio is 103.15. In terms of profitability, SRXH's ROE is +4.36%, compared to ABBV's ROE of +0.68%. Regarding short-term risk, SRXH is more volatile compared to ABBV. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check ABBV's competition here
SRXH vs NVS Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, NVS has a market cap of 282.5B. Regarding current trading prices, SRXH is priced at $0.13, while NVS trades at $148.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas NVS's P/E ratio is 21.21. In terms of profitability, SRXH's ROE is +4.36%, compared to NVS's ROE of +0.32%. Regarding short-term risk, SRXH is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check NVS's competition here
SRXH vs AZN Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, AZN has a market cap of 281.8B. Regarding current trading prices, SRXH is priced at $0.13, while AZN trades at $181.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas AZN's P/E ratio is 27.32. In terms of profitability, SRXH's ROE is +4.36%, compared to AZN's ROE of +0.22%. Regarding short-term risk, SRXH is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check AZN's competition here
SRXH vs MRK Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, MRK has a market cap of 275.1B. Regarding current trading prices, SRXH is priced at $0.13, while MRK trades at $111.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas MRK's P/E ratio is 31.38. In terms of profitability, SRXH's ROE is +4.36%, compared to MRK's ROE of +0.18%. Regarding short-term risk, SRXH is more volatile compared to MRK. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check MRK's competition here
SRXH vs AMGN Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, AMGN has a market cap of 176.1B. Regarding current trading prices, SRXH is priced at $0.13, while AMGN trades at $326.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas AMGN's P/E ratio is 22.71. In terms of profitability, SRXH's ROE is +4.36%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, SRXH is more volatile compared to AMGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check AMGN's competition here
SRXH vs GILD Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, GILD has a market cap of 160.9B. Regarding current trading prices, SRXH is priced at $0.13, while GILD trades at $129.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas GILD's P/E ratio is 15.48. In terms of profitability, SRXH's ROE is +4.36%, compared to GILD's ROE of +0.42%. Regarding short-term risk, SRXH is more volatile compared to GILD. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check GILD's competition here
SRXH vs PFE Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, PFE has a market cap of 144.4B. Regarding current trading prices, SRXH is priced at $0.13, while PFE trades at $25.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas PFE's P/E ratio is 19.34. In terms of profitability, SRXH's ROE is +4.36%, compared to PFE's ROE of +0.08%. Regarding short-term risk, SRXH is more volatile compared to PFE. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check PFE's competition here
SRXH vs BMY Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, BMY has a market cap of 116.4B. Regarding current trading prices, SRXH is priced at $0.13, while BMY trades at $57.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas BMY's P/E ratio is 15.97. In terms of profitability, SRXH's ROE is +4.36%, compared to BMY's ROE of +0.39%. Regarding short-term risk, SRXH is more volatile compared to BMY. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check BMY's competition here
SRXH vs SNY Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, SNY has a market cap of 102.8B. Regarding current trading prices, SRXH is priced at $0.13, while SNY trades at $42.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas SNY's P/E ratio is 18.40. In terms of profitability, SRXH's ROE is +4.36%, compared to SNY's ROE of +0.11%. Regarding short-term risk, SRXH is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check SNY's competition here
SRXH vs GSK Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, GSK has a market cap of 99.9B. Regarding current trading prices, SRXH is priced at $0.13, while GSK trades at $49.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas GSK's P/E ratio is 12.83. In terms of profitability, SRXH's ROE is +4.36%, compared to GSK's ROE of +0.28%. Regarding short-term risk, SRXH is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check GSK's competition here
SRXH vs ZTS Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, ZTS has a market cap of 31.1B. Regarding current trading prices, SRXH is priced at $0.13, while ZTS trades at $74.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas ZTS's P/E ratio is 12.18. In terms of profitability, SRXH's ROE is +4.36%, compared to ZTS's ROE of +0.62%. Regarding short-term risk, SRXH is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check ZTS's competition here
SRXH vs BIIB Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, BIIB has a market cap of 28.5B. Regarding current trading prices, SRXH is priced at $0.13, while BIIB trades at $192.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas BIIB's P/E ratio is 20.73. In terms of profitability, SRXH's ROE is +4.36%, compared to BIIB's ROE of +0.08%. Regarding short-term risk, SRXH is more volatile compared to BIIB. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check BIIB's competition here
SRXH vs HZNP Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, SRXH is priced at $0.13, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas HZNP's P/E ratio is 61.86. In terms of profitability, SRXH's ROE is +4.36%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, SRXH is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check HZNP's competition here
SRXH vs GRFS Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, GRFS has a market cap of 6.5B. Regarding current trading prices, SRXH is priced at $0.13, while GRFS trades at $7.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas GRFS's P/E ratio is 10.94. In terms of profitability, SRXH's ROE is +4.36%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, SRXH is more volatile compared to GRFS. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check GRFS's competition here
SRXH vs OGN Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, OGN has a market cap of 3.5B. Regarding current trading prices, SRXH is priced at $0.13, while OGN trades at $13.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas OGN's P/E ratio is 14.41. In terms of profitability, SRXH's ROE is +4.36%, compared to OGN's ROE of +0.30%. Regarding short-term risk, SRXH is more volatile compared to OGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check OGN's competition here
SRXH vs CELG-RI Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, CELG-RI has a market cap of 264.4M. Regarding current trading prices, SRXH is priced at $0.13, while CELG-RI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, SRXH's ROE is +4.36%, compared to CELG-RI's ROE of +0.39%. Regarding short-term risk, SRXH is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for SRXH.Check CELG-RI's competition here
SRXH vs CTOR Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, CTOR has a market cap of 83.9M. Regarding current trading prices, SRXH is priced at $0.13, while CTOR trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas CTOR's P/E ratio is -3.06. In terms of profitability, SRXH's ROE is +4.36%, compared to CTOR's ROE of -0.55%. Regarding short-term risk, SRXH is more volatile compared to CTOR. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check CTOR's competition here
SRXH vs SCLX Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, SCLX has a market cap of 53.4M. Regarding current trading prices, SRXH is priced at $0.13, while SCLX trades at $6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas SCLX's P/E ratio is -0.17. In terms of profitability, SRXH's ROE is +4.36%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, SRXH is more volatile compared to SCLX. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check SCLX's competition here
SRXH vs MIRA Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, MIRA has a market cap of 40.5M. Regarding current trading prices, SRXH is priced at $0.13, while MIRA trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas MIRA's P/E ratio is -0.71. In terms of profitability, SRXH's ROE is +4.36%, compared to MIRA's ROE of -4.50%. Regarding short-term risk, SRXH is more volatile compared to MIRA. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check MIRA's competition here
SRXH vs SCLXW Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, SCLXW has a market cap of 1.4M. Regarding current trading prices, SRXH is priced at $0.13, while SCLXW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas SCLXW's P/E ratio is N/A. In terms of profitability, SRXH's ROE is +4.36%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, SRXH is more volatile compared to SCLXW. This indicates potentially higher risk in terms of short-term price fluctuations for SRXH.Check SCLXW's competition here
SRXH vs CRXT Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, CRXT has a market cap of 0. Regarding current trading prices, SRXH is priced at $0.13, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas CRXT's P/E ratio is -0.02. In terms of profitability, SRXH's ROE is +4.36%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, SRXH is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for SRXH.Check CRXT's competition here
SRXH vs BDSIW Comparison May 2026
SRXH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRXH stands at 4.3M. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, SRXH is priced at $0.13, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRXH currently has a P/E ratio of -0.74, whereas BDSIW's P/E ratio is N/A. In terms of profitability, SRXH's ROE is +4.36%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, SRXH is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for SRXH.Check BDSIW's competition here